Trial · NCT00478335
Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus
NCT00478335, Not applicable, Completed, University of Colorado, Denver; results first posted 2018-02-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus. Trials, record NCT00478335. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00478335
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus
- NCT number
- NCT00478335
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 4 participants, actual
- Lead sponsor
- University of Colorado, Denver
- Conditions
- Nephrogenic Diabetes Insipidus
- Interventions
- sildenafil, calcitonin, hydrochlorothiazide/amiloride, indomethacin, Placebo for sildenafil, placebo for calcitonin
- First posted
- 2007-05-24
- Last updated
- 2018-02-12
- Results first posted
- 2018-02-12
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 24h Urine Volume | 4-days | urine volume in mL/d |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | 24h Urine Volume | 4-days | urine volume in mL/d | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 24h Urine Volume | Experimental First Then Standard | Period 1 | 6475 | Standard Deviation 742 | urine volume in mL/d |
| 24h Urine Volume | Standard First Then Experimental | Period 1 | 4178 | Standard Deviation 590 | urine volume in mL/d |
| 24h Urine Volume | Experimental First Then Standard | Period 2 | 6652 | Standard Deviation 1305 | urine volume in mL/d |
| 24h Urine Volume | Standard First Then Experimental | Period 2 | 4188 | Standard Deviation 1679 | urine volume in mL/d |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Period 1 (4 Days) | STARTED | Experimental First Then Standard | 2 | |
| Period 1 (4 Days) | STARTED | Standard First Then Experimental | 2 | |
| Period 1 (4 Days) | COMPLETED | Experimental First Then Standard | 2 | |
| Period 1 (4 Days) | COMPLETED | Standard First Then Experimental | 2 | |
| Period 1 (4 Days) | NOT COMPLETED | Experimental First Then Standard | 0 | |
| Period 1 (4 Days) | NOT COMPLETED | Standard First Then Experimental | 0 | |
| Period 2 (4 Days) | STARTED | Experimental First Then Standard | 2 | |
| Period 2 (4 Days) | STARTED | Standard First Then Experimental | 2 | |
| Period 2 (4 Days) | COMPLETED | Experimental First Then Standard | 2 | |
| Period 2 (4 Days) | COMPLETED | Standard First Then Experimental | 2 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Experimental First Then Standard | ||
| Total, all-cause mortality | Standard First Then Experimental | ||
| Total, other adverse events | Experimental First Then Standard | 0 | 2 |
| Total, other adverse events | Standard First Then Experimental | 0 | 2 |
| Total, serious adverse events | Experimental First Then Standard | 0 | 2 |
| Total, serious adverse events | Standard First Then Experimental | 0 | 2 |
Source ClinicalTrials.gov
Papers8
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Experimental First Then Standard vs Standard First Then Experimental: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00478335
GET https://conductscience.org/api/trials/v1/NCT00478335/registered